

Housekeeping Items

- Welcome to L.A. Care Provider Continuing Education (PCE) Program's Live Webinar!
- Webinar participants are muted upon entry and exit of webinar.
- Webinar is being recorded.
- Webinar attendance will be noted via log in. <u>2 Requirements</u>: <u>Please log in through a computer (instead of cell phone) to Join Webinar / Join Event and also call in by telephone by choosing the Call In Option with the call in number, access code and assigned unique attendee ID number. If your name does not appear on the WebEx Final Attendance and Activity Report (only as Caller User #) and no submission of online survey, no CME or CE certificate will be provided.</u>
- Questions will be managed through the Chat box and will be answered at the end of the presentation. *Please keep your questions brief and send to All Panelists.* One of our Learning and Development Team members will read the questions in the Chat box when it's time for Q & A session (last 30 minutes of live webinar).
- Please send a message to the Host via Chat box if you cannot hear the presenter or see the presentation slides.



L.A. Care PCE Program Friendly Reminders

- Partial credits are not allowed at L.A. Care's CME/CE activities for those who log in late (more than 15 minutes late) and/or log off early.
- The PowerPoint Presentation is allotted 60 minutes and last 30 minutes for Q&A session, total of 90-minute webinar, 1.50 CME credits for L.A. Care Providers and other Physicians, 1.50 CE credits for NPs, RNs, LCSWs, LMFTs, LPCCs, LEPs, and other healthcare professionals. A Certificate of Attendance will be provided to webinar attendees without credentials.
- <u>Friendly Reminder</u>, a survey will pop up on your web browser after the webinar ends (please do not close your web browser and wait a few seconds) and please complete the survey. <u>Please note</u>: the online survey may appear in another window or tab after the webinar ends.
- Within two (2) weeks after webinar and upon completion of the online survey, you will receive the
 pdf CME or CE certificate based on your credential and after verification of your name and
 attendance duration time of at least 75 minutes for this 90-minute webinar. The PDF webinar
 presentation will be available within 3 weeks after webinar date on lacare.org website located at
 https://www.lacare.org/providers/provider-central/provider-programs/classes-seminars
- Any questions about L.A. Care Health Plan's Provider Continuing Education (PCE) Program and our CME/CE activities, please email Leilanie Mercurio at Imercurio@lacare.org

Presenter's Bio

Sande Okelo, MD, PhD

- As a pediatric pulmonologist and researcher, Dr. Okelo is interested in improving asthma care for children, particularly those children at risk for poor care and poor asthma outcomes. He has developed an asthma specialist clinic for children that incorporates clinical care, patient education and clinical research. Dr. Okelo's research interests range from physician decision-making regarding asthma treatment to the development of strategies to improve asthma care.
- Associate Professor of Pediatrics, UCLA
- Director, Pediatric Asthma Center of Excellence, UCLA

Asthma Management in the Primary Care Setting

August 25, 2022

Live Webinar, 12:00 pm - 1:30 pm PST, 1.50 CME/CE Credits

Directly Provided CME / CE Activity by L.A. Care Health Plan

Sande Okelo, MD, PhD

UCLA Division of Pediatric Pulmonology and Sleep Medicine



Disclosures

The following CME planners and faculty do not have relevant financial relationships with ineligible companies:

- Leilanie Mercurio, L.A. Care PCE Program Manager, CME Planner
- Sande Okelo, MD, PhD, Associate Professor of Pediatrics, UCLA;
 Director, UCLA Pediatric Asthma Center of Excellence, CME Planner and Faculty

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Commercial support was not received for this CME/CE activity.

Cultural and Linguistic Competency (CLC)

This presentation includes content or topics that address:

- Patient Demographics including Age, Race/Ethnicity, Gender, Sexual Orientation
- Language/ Communication
- Religion
- Socioeconomics
- Physical Abilities / Qualities
- Awareness and Attitude Towards Cultural Differences
- Health Literacy
- Disparities in Care, Education, Geographic Location

Course Outline

- 1. Asthma diagnosis
- 2. Asthma assessment questionnaire in asthma management
- 3. 2020 Asthma Guideline Updates: intermittent inhaled steroids and SMART therapy
- 4. Case-based learning

Learning Objectives

- 1. List the three (3) asthma diagnostic criteria from national asthma guidelines.
- 2. Summarize how to incorporate an asthma assessment questionnaire into clinical practice.
- 3. Identify the four (4) levels of asthma severity (intermittent, mild persistent, moderate persistent, severe persistent) using an asthma assessment questionnaire.
- 4. Review changes in asthma management in the 2020 NIH Asthma Guidelines: intermittent inhaled steroids and SMART therapy.

A few thoughts before we start...

- 1. Asthma is simple but not easy
- 2. When not diagnosing or not treating asthma, are you doing harm?
 - How do you know?
- 3. Your asthma care should be a results-driven process
 - 1. Is your patient doing well or not?
 - 1. How do you know?
- 4. No standardization of assessment = poor care

NIH Asthma Guidelines: Expert Panel Reports: Systematic Review of Evidence + Expert Opinion





GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

Updated 2021

GINA Asthma Guidelines 2021

CONTROL-BASED ASTHMA MANAGEMENT

In control-based asthma management, pharmacological and non-pharmacological treatment is adjusted in a continuous cycle that involves assessment, treatment and review (Box 3-2). Asthma outcomes have been shown to improve after the introduction of control-based guidelines or practical tools for implementation of control-based management strategies. The concept of control-based management is also supported by the design of most randomized controlled medication trials, with patients identified for a change in asthma treatment on the basis of features of poor symptom control with or without other risk factors such as low lung function or a history of exacerbations.



Diagnosis



To establish a diagnosis of asthma, determine that:

- Asthma symptoms occur more than once
 - Cough
 - Wheeze
 - Chest pain/tightness
 - Shortness of breath (exertional)
 - Decreased stamina
- Asthma symptoms improve with asthma medicines
 - Adequate dose, duration and echnique
- Alternative diagnoses are excluded
 - Habit cough; chronic sinusitis; GERD




Course Outline

1. Asthma diagnosis

2. Asthma assessment questionnaire in asthma management

3. 2020 Asthma Guideline Updates: intermittent inhaled steroids and SMART therapy

4. Case-based learning



Pediatric Asthma Control & Communication Instrument Asthma Symptoms 7. Over the **past week**, how many days Days has your child had asthma symptoms? For example: 1-2 Every day Every day (not all day long) (all day long) Cough • Chest tightness • Shortness of X breath • Sputum (spit, mucous, phlegm when coughing) • Difficulty taking a deep breath Wheezy or whistling sound in the chest Reliever use 8. Over the past week, how many days Days have you had to give your child medicine to quickly relieve asthma 1-2 Every day Every day symptoms? For example: (not all day long) (all day long) Albuterol Inhaler Spray Machine Nebulizer Pump Attacks 9. Over the past week, how many days did Davs your child have an asthma attack? For example: • When it is harder for your child to breathe When you give your child more asthma medicine When the asthma medicine does not work **Activity Limitation** 10. Over the past week, how much has Not Verv at all Slightly Moderately much Completely asthma limited your child's activities? Nighttime Symptoms 11. Now for this question, please answer Nights about the past 2 weeks. How many nights did your child's asthma keep your child from sleeping or wake him/her up in the past 2 weeks? For clinician use only - Asthma Control Assignment Mild Mild Moderate Assign patient's current level of asthma control by looking at box intermittent persistent persistent per<u>s</u>istent checked farthest to the right on questions 7-11 and match color of this box to level of asthma control in this section and circle and/or document in patient's chart Controlled Not Controlled

Patient and/or Parent Completes in Waiting/Exam Room

Complete at every encounter

Clinic, Urgent Care, ED, Hospital


Enlist team members to use systematically

Lack of use risks inaccurate estimation of asthma control/ severity

If unable to use, consider lower threshold for specialist referral


Use to drive care

When to start Rescue Medication?



Follow-up in 2-6 wks to confirm asthma is controlled


When to Follow-up?



Follow-up in 2-6 wks to confirm asthma is controlled


Follow-up in 2 – 3 months to confirm asthma remains controlled

When to start Daily Controller Medications?




Follow-up in 2-6 wks to confirm asthma is controlled

When to start oral steroids?



Follow-up in 2-6 wks to confirm asthma is controlled


When to step-down or stop treatment?



When controlled for >=3 months


When controlled for >=12 months if hospitalized and/or required oral steroids

When to refer to asthma specialist?



Learning Objectives

- 1. Asthma diagnosis
- 2. Asthma assessment questionnaire in asthma management
- 3. 2020 Asthma Guideline Updates: intermittent inhaled steroids and SMART therapy
- 4. Case-based learning



Organization and Topics

- 6 Sections (19 Questions; 14 Recommendations)
 - Use of Exhaled Nitric Oxide in Diagnosis and Mgmt of Asthma
 - a. 5 Questions; 4 Recommendations
 - 2. Indoor Allergen Mitigation in Mgmt of Asthma
 - a. 1 Question; 4 Recommendations
 - 3. Use of Intermittent Inhaled Steroids (ICS) in the Treatment of Asthma
 - a. 3 Questions; 5 Recommendations
 - 4. Use of Long-Acting Muscarinic Antagonists for Asthma
 - a. 3 Questions; 3 Recommendations
 - 5. Subcut. and Sublingual Immunotherapy in the Tx of Allergic Asthma
 - a. 2 Questions; 2 Recommendations
 - 6. Use of Bronchial Thermoplasty to Improve Asthma Outcomes
 - a. 1 Question; 1 Recommendation



Organization and Topics

- 6 Sections (19 Questions; 14 Recommendations)
 - Use of Exhaled Nitric Oxide in Diagnosis and Mgmt of Asthma
 - a. 5 Questions; 4 Recommendations
 - 2. Indoor Allergen Mitigation in Mgmt of Asthma
 - a. 1 Question; 4 Recommendations
 - 3. Use of Intermittent ICS in the Treatment of Asthma
 - a. 3 Questions; 5 Recommendations
 - 4. Use of Long-Acting Muscarinic Antagonists for Asthma
 - a. 3 Questions; 3 Recommendations
 - 5. Subcut. and Sublingual Immunotherapy in the Tx of Allergic Asthma
 - a. 2 Questions; 2 Recommendations
 - 6. Use of Bronchial Thermoplasty to Improve Asthma Outcomes
 - a. 1 Question; 1 Recommendation



Intermittent ICS in Asthma

- 1. What is the comparative effectiveness of intermittent ICS for recurrent wheezing in children 0 − 4 years old?
- 2. What is the comparative effectiveness of intermittent ICS in patients 5 years of age and older with mild persistent asthma?
- 3. What is the comparative effectiveness of ICS-LABA (formoterol) combination therapy as both maintenance and rescue therapy in patients 5 years of age and older with persistent asthma?

- 1. What is the effectiveness of <u>intermittent ICS</u> for <u>recurrent</u> wheezing in children 0 4 years old?
 - Recurrent Wheezing
 - 3+ lifetime episodes or 2+ episodes in the past year
 - Budesonide (1mg neb BID) + QID Albuterol <u>OR</u>
 - Fluticasone (750mcg BID) + QID Albuterol
 - x 7 10 days

- 2. What is the effectiveness of <u>intermittent ICS</u> in patients 5+ years old with <u>mild persistent</u> asthma?
- Not Recommended for Patients <12 Years Old
- For patients 12+ years old, not on a daily inhaled steroid
 - QVAR 40: 2 6 puffs q4 hours + Albuterol 2 4 puffs q4 hours
 - •QVAR 80: 1 3 puffs q4 hours + Albuterol 2 4 puffs q4 hours
- No doubling, quadrupling or quintupling of daily inhaled steroid as needed

- 3. What is the effectiveness of ICS-LABA (formoterol) as both maintenance and rescue therapy in patients 5+ years old with persistent asthma?
- For patients with **moderate-severe persistent** asthma
- ICS-LABA = ICS-formoterol ONLY
 - Mometasone-Formoterol (Dulera): 100/5; 200/5
 - Budesonide-Formoterol (Symbicort): 80/4.5; 160/4.5
- One medicine for $\underline{\mathbf{M}}$ aintenance and $\underline{\mathbf{R}}$ escue $\underline{\mathbf{T}}$ reatment = $\underline{\mathbf{M}}$
 - Single inhaler for Maintenance and Rescue Treatment = SMART



123 A

123 ACC

Allergy Respiratory Treatments










Dulera 200

























30 30





Symbicort®

budesonide and

80/4.5, 160/4.5 mcg

formoterol fumarate





ontain both long-acting beta₂-agonist (LABA) and long-acting muscarinic antagonist (LAMA) Anoro® Ellipta® 62.5/25 mcg

Aerosphere® umeclidinium and 9/4.8 mcg vilanterol inhalation glycopyrrolate and



Stiolto™ Respimat® 2.5/2.5 mcg

formateral fumerate


Bevespi



Utibron™ Neohaler®

27.5/15.6 mcg indacaterol and glycopyrrolate inhalation powder





Trelegy® Ellipta® 100/62.5/25 mcg fluticasone furoate umeclidinium and vilanterol inhalation





Symbicort 80

123

A G



Symbicort 160







COMBINATION Combivent[®] Respimat®

















SMART (Single Maintenance and Rescue Therapy)

• Maintenance = 1 - 2 puffs qD - BID



• Rescue = 1 - 2 puffs BID - TID

- Total Puffs/Day: varies by age:
 - •4 11 years old: 8 puffs/day total (maintenance + rescue)
 - •12+ years old: 12 puffs/day total (maintenance + rescue)

SMART Therapy: "Puff" Math

| 7.90 | Day | Puffs/ Day | Day (prn) | Maintenance + Rescue |
|-----------------|-----|------------|------------|-------------------------|
| 4 – 11 Years | 8 | 1puff qD | 2puffs TID | 2puffs TID – QID |
| 4 – 11 Years | 8 | 2puffs qD | 2puffs TID | 2puffs QID |
| 4 – 11 | 8 | 2puffs BID | 2puffs BID | 2puffs QID |

3puffs TID

3puffs TID

2puffs TID

Total Puffs/ Maintenance Rescue Puffs/ Final Regimen =

1puff qD

2puff qD

2puff BID

12

12

12

Years

12+

12+

12+

Years

Years

Years

2puffs BID 2putts **QID**

3puffs QID or 4 puffs TID

3puffs QID or 4 puffs TID

3puffs **QID** or 4 puffs **TID**

35

Limitations of SMART Strategy

Insurance formularies may not cover ICS-formoterol preparations

- Patient will likely need to always have 2 inhalers
 - 120 actuations/inhaler
 - •4 puffs/day → 30 days of use
 - •8 puffs/day → 15 days of use
 - •12 puffs/day → 10 days of use
 - Mail order?
- May need to pursue "traditional" treatment
 - ICS-salmeterol + as needed albuterol/xopenex



Summary of 2020 NIH Asthma Guidelines Updates

| Age | Intermittent (ICS)? | Asthma Type | Regimen | Notes |
|----------------|------------------------|----------------------|---|----------------------------|
| 0 - 4 Years | Yes | Viral-induced asthma | Budesonide 1mg neb BID + QID Albuterol | x7 – 10 days ↓growth w/ |

Fluticasone

QVAR 40 q4 hours

QVAR 80 q4 hours

or 4puffs TID

750mcg BID + QID Albuterol

2 – 6 puff + Albuterol 2 – 4 puff

1 - 3 puff + Albuterol 2 - 4 puff

Dulera/Symbicort 2puffs QID

Dulera/Symbicort 3puffs QID

fluticasone

Daily ICS or ICS-

LABA +prn SABA

Daily ICS + prn

1-2puff qD – BID

if intermittent sx's

1-2puff qD – BID

if intermittent sx's

SABA

("recurrent

wheezing")

persistent

Mod-Severe

Mod-Severe

Persistent

Persistent

asthma

Mild

5 - 11

Years

Years

0 - 3

Years

4 - 11

Years

Years

12+

12+

No

Yes

SMART?

No

Yes

Yes

Oral Corticosteroids

Oral Steroids for Moderate/Severe Persistent Asthma 1mg/kg/day x3 – 10 days

Prednisolone (15mg/5ml)



Prednisolone (15mg/5ml)



<u>OraPred</u> (15mg/5ml)



w/ SABA or ICS-formoterol

PediaPred (5mg/5ml)



Prednisone Tabs

(1, 2.5, 5, 10, 20, 50mg)





Learning Objectives

- 1. Asthma diagnosis
- 2. Asthma assessment questionnaire in asthma management
- 3. 2020 Asthma Guideline Updates: intermittent inhaled steroids and SMART therapy
- 4. Case-based learning

AG: Original HPI

- AG is a 5 year old boy who has had nearly nightly coughing x3 months, worse over the past 2-4 weeks, and disruptive to sleep at least every 2 wks. There have been frequent interval URIs, when cough is more intensive. Coughing paroxysms (20 times in a row).
- Allegra was too sedating w/o relief of the cough (presumed post nasal drip).
- 2 puffs of albuterol, hypoallergenic bedding, humidifier have not relieved the cough.
- Required prednisone x2 over the prior year for wheezing.
 - prednisone & albuterol q4 x48 hrs relieved sx's within 24 hrs
- The allergist is recommending Singulair.




Why might this patient have asthma?

- Cough x3 months duration (>1 month)
- Nocturnal cough that is disruptive to sleep
- URIs induce coughing
- Reduced cough with use of prednisone and albuterol simultaneously


AG Initial Visit: 10/20/20

Dulera 100 (2p QID), pred x3


What to do? days + f/u in 2-6 wks



AG f/u Visit: 11/4/20 What to do? Dulera 100 (2p QID), pred x7 days + f/u in 2-6 wks




AG f/u Visit: 11/14/20 What to do? Dulera 200 (2p QID)+ f/u in 2-



AG f/u Visit: 1/18/21 What to do?

Dulera 200 (2p BID) + f/u in 1-3 mos



NC: Original HPI

NC is a 4 y.o. male with a history of respiratory infections with wheezing, resulting in hospitalization x2. He does have recurrent wheezing and chest congestion with URIs. He is well during the summer. The parents report no symptoms between illnesses and no symptoms during physical activity.

In the past, he has been treated with Budesonide nebs (0.25mg BID), prn URIs


Why might this patient have asthma?

Recurrent wheezing


URI-induced wheezing

NC Initial Visit: 1/21/21 Budesonide nebs 1mg BID x7 days + What to do? Albuterol QID, prn URI sx's. f/u in 1-3 mos

Common pattern for young children with URI-induced asthma



NC f/u Visit: 4/19/21 Continue tx: Budesonide 1mg BID x7 days + What to do? Albuterol QID, prn URI sx's. f/u in 3-6 mos



Additional Thoughts Beyond Asthma Care

Health care in the U.S. is consistently worse for ethnic/racial minorities

Racial bias (e.g., stereotypes) are a source of racial disparities in health care

Is empathy possible w/o relatability?

UNEAUMENT

CONFRONTING RACIAL AND ETHNIC DISPARITIES IN HEALTH CARE

Brian D. Smedley, Adrienne Y. Stith, and Alan R. Nelson, Editors


Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care

Board on Health Sciences Policy

OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS Washington, D.C. www.nap.edu

Racial Inequities in Asthma Care Despite Higher Levels of Asthma Morbidity in Black Patients



Adapted from EM Zoratti. AJRCCM 1998 Aug;158(2):371-7. Health service use by African Americans and Caucasians with asthma in a managed care setting




Background: Why Cultural Competency?

- Nearly half of the children in California are Hispanic and/or have a foreign-born parent.
- Currently one of three of families speak a language other than English
- ~50% of our children are from ethnic or racial "minority" groups
- One out of every 8 children in the United States lives in California



Better Asthma Care if Cultural Competency Present



Asthma Resources

NIH Asthma Guidelines

https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates

NIH Asthma Guidelines Digital Toolkit

https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates/digital-toolkit

GINA Asthma Guidelines

https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/

Asthma Surveys

https://www.uclahealth.org/mattel/pediatric-pulmonology/patient-forms

Thank You!

Sande Okelo, MD, PhD sokelo@mednet.ucla.edu

Division of Pediatric Pulmonology and Sleep Medicine UCLA Mattel Children's Hospital

FAQs

1. How often should a patient with well-controlled asthma be seen?

Answer: at least every 3 months.

2. There are so many asthma medication options—so what is a short-list of go-to asthma medications?

Answer: Two of the more commonly covered inhaled steroids are Flovent (44, 110, 220) and QVAR (40, 80).

- 3) When should a patient be referred to an asthma specialist? **Answers:** 1) patient request; 2) admitted for asthma; 3) asthma remains uncontrolled.
- 4) Can patients be treated with as needed controller medications? **Answer:** Yes. 1mg of budesonide nebulized BID x7 days, at the onset of each URI or Symbicort/Dulera (asthma symptoms <3 days/month): 2 puffs BID.

Q & A



L.A. Care PCE Program Friendly Reminders

<u>Friendly Reminder</u>, a survey will pop up on your web browser after the webinar ends (please do not close your web browser and wait a few seconds) and please complete the survey.

<u>Please note:</u> the online survey may appear in another window or tab after the webinar ends.

Upon completion of the online survey, you will receive the pdf CME or CE certificate based on your credential, verification of name and attendance duration time, within two (2) weeks after webinar.

Webinar participants will only have up to two weeks after webinar date to email Leilanie Mercurio at lmercurio@lacare.org to request the evaluation form if the online survey is not completed yet. No name, no survey or completed evaluation and less than 75 minutes attendance duration time via log in means No CME or CE credit, No CME or CE certificate.

Thank you!